Search PubMedSearch

PubMed · 8564992

Incident pain.

Abstract

Incident pain is a major problem for most patients with cancer pain. It is difficult to classify and poorly studied. The problem is that doses of opioids high enough to control episodic incident pain are too high when that pain is absent, leading to adverse effects. The commonest type of incident pain is pain on movement, leading to a quantitative increase in pain intensity. There is also a class of incident pain that is qualitatively different from any pain at rest, more akin to neuropathic pain. "Breakthrough" pain is the term used to describe pains that break through an existing analgesic regimen; these may be incident pains. There are no randomized controlled trials of incident pain management in cancer pain. The suggestions made for improving management are therefore based on such trials in other pain contexts. Studies in the cancer context will need to concentrate on characterizing the pain episodes.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H J McQuay, A R Jadad. 1994. Incident pain.. https://pubmed.ncbi.nlm.nih.gov/8564992/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Lack of cross-tolerance between the antinociceptive effect of intrathecal orphanin FQ and morphine in the rat.

We assessed whether tolerance develops to the antinociceptive effect of intrathecal (i.t.) orphanin FQ, the endogenous ligand of the orphan opioid-like receptor, and whether there is a cross-tolerance between the antinociceptive effect of i.t. orphanin FQ and the mu opioid receptor agonist morphine. Orphanin FQ administered i.t. at 10 micrograms induced strong thermal antinociception as assessed with the tail flick test without inducing motor impairment or sedation. Tolerance developed in 4 days to the antinociceptive effect of orphanin FQ upon twice daily injections. However, rats rendered tolerant to orphanin FQ did not exhibit cross-tolerance to morphine. Moreover, in rats made tolerant to morphine, orphanin FQ induced similar antinociceptive effect as in morphine naive rats. The present results are the first to show that there is no cross-tolerance between orphanin FQ and morphine in eliciting spinal antinociception, supporting the notion that orphanin FQ produced spinal antinociception through a site which is different from classical opioid receptors.

Analgesics, Opioid

Receptor-induced internalization of selective peptidic mu and delta opioid ligands.

The binding and internalization of radioiodinated and fluorescent mu and delta opioid peptides in mammalian cells were quantitatively studied by biochemical techniques and directly visualized by confocal microscopy. The labeled peptides were prepared by inserting either a 125I-Bolton-Hunter group or a fluorescent probe into the C-terminal part of 5-aminopentylamide derivatives of deltorphin-I and [Lys7]dermorphin. The purified derivatives kept most of their specificity and selectivity toward delta and mu opioid receptors, respectively. Biochemical and confocal microscopy data showed that both mu and delta opioid peptides were internalized in mammalian cells transfected with the corresponding opioid receptor according to a receptor-mediated mechanism. The internalization process was time- and temperature-dependent and was completely blocked by the endocytosis inhibitor phenylarsine oxyde. Internalization of both delta and mu ligands occurred from a single large cap at one pole of the cell, indicating that polymerization of ligand-receptor complexes preceeded internalization. Finally, green and red fluorescent analogues of deltorphin-I and [Lys7]dermorphin, respectively, were found to internalize through partly distinct endocytic pathways in cells co-transfected with mu and delta receptors, suggesting that each of these receptors interacts with distinct proteins mediating intracellular sorting and trafficking.

Analgesics, Opioid